Growth of sales under the Affordable Medicines program that reimburses the cost of medicines has suspended, and pharmaceutical manufacturers are waiting for the expansion of the list of diseases under the program, Marketing and Sales Director at PJSC Farmak Susana Khalilova has said. “As for the Affordable Medicines program, it seems that the further quantitative growth in sales of medicines has stopped. A fuss about it has fallen. A more or less clear number of patients has been formed,” she said in an interview with Interfax-Ukraine. She said that “it was simply a “madhouse” at the beginning of the Affordable Medicines program – pharma companies could not guess the necessary number of medicines.”
“A year has passed and we understand approximately how many and what preparations are needed. Patients calmed down a bit and do not buy two or three packages to have them for the future. It took time to establish the process,” she said.
According to Khalilova, the Ministry of Health had to calculate the number of medicines required for participation in the program. “If the state at the very beginning have said how much money it would spend on a certain molecule or announced the approximate consumption of the concrete drug, it would have been much easier,” she said. In addition, Khalilova said that Farmak receives information on cases of a lack of budget funds for the Affordable Medicines program.
Farmak is a member of the Association Manufacturers of Medications of Ukraine (AMMU).
